Vorinostat
| Code | Size | Price |
|---|
| SYN-3006-M100 | 100 mg | Enquire |
Quantity:
| SYN-3006-M005 | 5 mg | £57.00 |
Quantity:
| SYN-3006-M010 | 10 mg | £69.00 |
Quantity:
| SYN-3006-M050 | 50 mg | £92.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
Ambient
Storage:
+4°C
Documents
Further Information
Alternate Names/Synonyms:
SAHA; Suberoyl anilide bishydroxamide; Suberoylanilide hydroxamic acid;
Appearance:
Solid.
CAS:
149647-78-9
EClass:
32160000
Form (Short):
liquid
GHS Symbol:
GHS08
Hazards:
H361
InChi:
InChI=1S/C14H20N2O3/c17-13(15-12-8-4-3-5-9-12)10-6-1-2-7-11-14(18)16-19/h3-5,8-9,19H,1-2,6-7,10-11H2,(H,15,17)(H,16,18)
InChiKey:
WAEXFXRVDQXREF-UHFFFAOYSA-N
Long Description:
Chemical. CAS: 149647-78-9. Formula: C14H20N2O3. MW: 264.3. Vorinostat (SAHA, MK0683, Zolinza) inhibits the enzymatic activity of histone deacetylases HDAC1, HDAC2 and HDAC3 (Class I) and HDAC6 (Class II) at nanomolar concentrations (IC50< 86 nM). These enzymes catalyze the removal of acetyl groups from the lysine residues of histones proteins. In some cancer cells, there is an overexpression of HDACs, or an aberrant recruitment of HDACs to oncogenic transcription factors causing hypoacetylation of core nucleosomal histones. By inhibiting histone deacetylase, vorinostat causes the accumulation of acetylated histones and induces cell cycle arrest and/or apoptosis of some transformed cells. The mechanism of the antineoplastic effect of vorinostat has not been fully characterized.
MDL:
MFCD00945317
Molecular Formula:
C14H20N2O3
Molecular Weight:
264.3
Package Type:
Plastic Vial
PG:
III
Precautions:
P201, P281
Product Description:
Vorinostat (SAHA, MK0683, Zolinza) inhibits the enzymatic activity of histone deacetylases HDAC1, HDAC2 and HDAC3 (Class I) and HDAC6 (Class II) at nanomolar concentrations (IC50< 86 nM). These enzymes catalyze the removal of acetyl groups from the lysine residues of histones proteins. In some cancer cells, there is an overexpression of HDACs, or an aberrant recruitment of HDACs to oncogenic transcription factors causing hypoacetylation of core nucleosomal histones. By inhibiting histone deacetylase, vorinostat causes the accumulation of acetylated histones and induces cell cycle arrest and/or apoptosis of some transformed cells. The mechanism of the antineoplastic effect of vorinostat has not been fully characterized.
Purity:
>95%
Signal word:
Danger
Solubility Chemicals:
Soluble in DMSO or ethanol. Almost insoluble in water.
Transportation:
Excepted Quantity
UNSPSC Category:
Protein Kinase Modulators
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 2 years after receipt when stored at -20°C.
References
Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of gamma-H2AX foci: A. Munshi, et al.; Mol. Cancer Ther. 5, 1967 (2006) | Poly(beta-amino ester) nanoparticles enable tumor-specific TRAIL secretion and a bystander effect to treat liver cancer: H.J. Vaughan, et al.; Mol. Ther. Oncolytics 21, 377 (2021)
Related Products
| Product Name | Product Code | Supplier | Apicidin | AG-CN2-0087 | AdipoGen Life Sciences | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MS-275 | AG-CR1-0032 | AdipoGen Life Sciences | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Quisinostat | SYN-3029 | AdipoGen Life Sciences | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||